E-viri
Recenzirano
-
Reilly, R M; Kirsh, J; Gallinger, S; Thiessen, J J; Damani, M; Hay, K; Polihronis, J; Schmocker, B; Odze, R; Houle, S
Nuclear medicine and biology 20, Številka: 1Journal Article
Sixteen patients with colorectal cancer were administered 37-74 MBq (1 mg) of radioiodinated B72.3 monoclonal antibody. Pharmacokinetic analysis was carried out on plasma and urine samples. Elimination from the plasma was biexponential with a mean T1/2 alpha of 3.7 h and T1/2 beta of 62.4 h. The plasma clearance was fit to a two-compartmental model. This was combined with a previously reported model for radioiodine to construct a composite model. There was a good correlation (r = 0.952) between the model-predicted and observed excretion of radioiodine suggesting that the composite model is compatible with the pharmacokinetics of the radiolabelled antibody.
